Epstein-Barr virus-derived peptide–Major Histocompatibility Complex class II complex (EBV peptide–MHC II) (EBV peptide–MHC II)

Epstein-Barr virus (EBV)-derived peptide–Major Histocompatibility Complex (MHC) class II complexes are specialized molecular structures formed when viral proteins, such as EBNA1, LMP1, or LMP2, are processed into peptides and loaded onto MHC class II molecules (Long et al., 2011, Frontiers in Immunology). These complexes are typically displayed on the surface of B cells, which are the primary reservoir for EBV, as well as professional antigen-presenting cells and certain EBV-associated tumor cells (Taylor et al., 2015, Nature Reviews Immunology). Their primary biological function is to serve as the ligand for the T-cell receptor (TCR) on CD4+ T cells, initiating an immune response characterized by cytokine secretion and direct help for B-cell and CD8+ T-cell activity. In therapeutic contexts, these complexes are targeted by adoptive T-cell therapies, such as tabelecleucel (Ebvallo), which utilize EBV-specific T cells to recognize and kill malignant cells in patients with post-transplant lymphoproliferative disorder (Prockop et al., 2020, JCI). Furthermore, research into multiple sclerosis has highlighted these complexes as potential drivers of autoimmunity, where EBV-specific immune responses may cross-react with central nervous system antigens through molecular mimicry (Bjornevik et al., 2022, Science).

Other names

EBV pMHC IIEBV-specific MHC class II-peptide complexEpstein-Barr virus antigen-MHC II complex

Recognition by specific T-cell receptors (TCRs) on CD4+ T lymphocytes, triggering targeted cytotoxicity and cytokine production against EBV-infected or transformed cells (Prockop et al., 2020, JCI).